Selzatin Tablets (Nizatidine)

Adult dose

Treatment of active gastric or duodenal ulcers: Adults take 300mg of nizatidine once daily at bedtime, or 150mg twice daily, in the morning and evening, by mouth. Most ulcers heal within 4 weeks, but treatment may be continued for up to 8 weeks if necessary. For active gastric ulcers, malignancy must be ruled out before treatment. Prevention of duodenal ulcer recurrence: After healing of a duodenal ulcer, adults take 150mg by mouth once daily at bedtime. Treatment may continue for up to 1 year; results of longer-term administration are unknown. Gastroesophageal reflux disease: Adults take 150mg by mouth twice daily, in the morning and evening. Treatment may continue for up to 12 weeks. Improvement of gastric mucosal lesions: Adults take 150mg by mouth twice daily, in the morning and evening, for 2 weeks. Dosage adjustment for patients with severe renal impairment: Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: Creatinine clearance 20~50 ml/min: 150mg once daily Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: Creatinine clearance < 20 ml/min: 150mg every other day Maintenance therapy: Creatinine clearance 20~50 ml/min: 150mg every other day Maintenance therapy: Creatinine clearance < 20 ml/min: 150mg every 3 days Some elderly patients may have creatinine clearance below 50mL/min. Based on pharmacokinetic data in patients with renal impairment, the dose should be reduced in these patients in accordance with their reduced renal function. The clinical effects of this dose reduction in patients with renal impairment have not been evaluated.

This drug should not be used in patients who have had an allergic reaction to this drug or other H2-receptor antagonists. Precautions should be taken when using this drug in patients with a history of allergic reactions to medication, patients with poor liver function, and patients with kidney-related issues. Patients with reduced kidney function may have elevated levels of this drug, and the dosage should be reduced or the interval between doses extended. If allergic symptoms such as rash, itching, or difficulty breathing occur during treatment, the medication should be stopped immediately. Blood abnormalities may manifest as anemia, leukopenia, or thrombocytopenia, so consult a physician if symptoms arise. Gastrointestinal symptoms such as constipation, diarrhea, dry mouth, and nausea may occur. There may be liver function abnormalities, so symptoms of hepatitis or jaundice should be reported to medical personnel immediately. Neurological symptoms such as confusion, headache, drowsiness, and dizziness may rarely occur. Be cautious as asymptomatic ventricular tachycardia may occur. In women, breast enlargement may rarely occur, and erectile dysfunction or decreased libido have also been reported. Skin reactions such as rash, sweating, and urticaria may develop, so report any skin abnormalities. This drug may cause hyperuricemia unrelated to gout or kidney stones. It could conceal symptoms of gastric cancer, so it should be used only after confirming that it is not a malignant condition. Since this drug is primarily excreted through the kidneys, dosage adjustments may be necessary for patients with moderate to severe kidney impairment. If there is no therapeutic effect, it is better to switch to another drug, and liver and kidney function as well as blood conditions should be monitored regularly. Pregnant women or those who may become pregnant should carefully consider the risks and benefits of using this drug. Breastfeeding women should use this drug only when absolutely necessary, and safety in pediatric patients has not been established. Elderly patients are more likely to have reduced kidney function, so kidney function tests should be conducted before administration and monitored closely during treatment. This drug may affect the results of certain clinical tests, so inform the testing personnel of its use. Overdose may result in symptoms such as vomiting, diarrhea, and increased salivation, with no specific antidote but treatment should be given based on symptoms. Long-term high-dose administration has a low risk of carcinogenicity or genotoxicity, although adverse effects such as liver damage have been observed in animal experiments. In animal studies during pregnancy, some fetal malformations have been reported, so caution is warranted when using during pregnancy, and drug excretion into breast milk can also occur, warranting caution during lactation.

• Rash
• itching
• bronchial asthma
• laryngeal edema
• anaphylaxis symptoms
• anemia
• leukopenia
• neutrophilia
• thrombocytopenic purpura
• constipation

This drug should be stored in a tightly closed container to protect it from air and moisture. It is best to keep it in a cool place at a temperature between 15 and 30 degrees.

Appearance

Yellow round film-coated tablets

Package unit

30 tablets/bottle, 500 tablets/bottle